Paychex (PAYX) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.24 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1.61%. A quarter ago, it was expected that this payroll processor and human-resources services provider would post earnings of $1.21 per share when it actually produced earnings of $1.22, delivering a surprise of +0.83%.O ...

Core Insights - Movado (MOV) reported quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.57 per share, but showing an increase from $0.37 per share a year ago, resulting in an earnings surprise of -21.05% [1] - The company posted revenues of $186.13 million for the quarter ended October 2025, slightly surpassing the Zacks Consensus Estimate by 0.13% and showing growth from $182.73 million year-over-year [2] - Movado has surpassed consensus revenue estimates two times over the last four quarters, while it has only exceeded consensus EPS estimates once in the same period [2] Earnings Outlook - The sustainability of Movado's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.67 on revenues of $180.22 million, and for the current fiscal year, it is $1.44 on revenues of $659.71 million [7] Industry Context - The Retail - Jewelry industry, to which Movado belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Movado's stock performance [5][6]

Core Insights - Central Garden (CENTA) reported a quarterly loss of $0.09 per share, better than the Zacks Consensus Estimate of a loss of $0.20, and improved from a loss of $0.18 per share a year ago, resulting in an earnings surprise of +55.00% [1] - The company achieved revenues of $678.18 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.82% and showing an increase from $669.49 million year-over-year [2] - Central Garden shares have declined approximately 11.5% year-to-date, contrasting with the S&P 500's gain of 12.3% [3] Financial Performance - Over the last four quarters, Central Garden has exceeded consensus EPS estimates four times and topped consensus revenue estimates twice [2] - The current consensus EPS estimate for the upcoming quarter is $0.22 on revenues of $661.29 million, while for the current fiscal year, it is $2.73 on revenues of $3.16 billion [7] Market Outlook - The company's stock performance in the near term will largely depend on management's commentary during the earnings call and the sustainability of the stock's price movement based on recent earnings and future expectations [3][4] - The Zacks Rank for Central Garden is currently 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Industry Context - The Consumer Products - Discretionary industry, to which Central Garden belongs, is currently ranked in the bottom 27% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Central Garden's stock performance [5]

分组1 - Atkore Inc. reported quarterly earnings of $0.69 per share, missing the Zacks Consensus Estimate of $1.3 per share, and down from $2.43 per share a year ago, representing an earnings surprise of -46.92% [1] - The company posted revenues of $752.01 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.77%, but down from year-ago revenues of $788.3 million [2] - Atkore shares have lost about 20.3% since the beginning of the year, contrasting with the S&P 500's gain of 12.9% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.97 on revenues of $648.1 million, and for the current fiscal year, it is $5.41 on revenues of $2.84 billion [7] - The Wire and Cable Products industry, to which Atkore belongs, is currently in the top 37% of the Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

分组1 - Cadiz reported a quarterly loss of $0.1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of -11.11% [1] - The company posted revenues of $4.15 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 6.39%, and showing an increase from $3.22 million year-over-year [2] - Over the last four quarters, Cadiz has not surpassed consensus EPS estimates and has topped revenue estimates only once [2] 分组2 - The stock has underperformed, losing about 11.5% since the beginning of the year, while the S&P 500 gained 16.5% [3] - The current consensus EPS estimate for the coming quarter is $0.54 on revenues of $3.9 million, and for the current fiscal year, it is $0.24 on revenues of $14.9 million [7] - The Agriculture - Operations industry, to which Cadiz belongs, is currently ranked in the bottom 21% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Insights - OmniAb, Inc. reported a quarterly loss of $0.14 per share, which aligns with the Zacks Consensus Estimate, showing an improvement from a loss of $0.16 per share a year ago [1] - The company's revenues for the quarter ended September 2025 were $2.24 million, missing the Zacks Consensus Estimate by 62.97% and down from $4.17 million year-over-year [2] - OmniAb's shares have declined approximately 58.2% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Financial Performance - The company has surpassed consensus EPS estimates only once in the last four quarters [1] - The current consensus EPS estimate for the upcoming quarter is -$0.15 on revenues of $7.15 million, and for the current fiscal year, it is -$0.59 on revenues of $21.52 million [7] Market Outlook - The earnings outlook and management's commentary during the earnings call will be crucial for assessing the stock's immediate price movement [3][4] - The Zacks Rank for OmniAb is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Medical - Drugs industry, to which OmniAb belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable environment for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

分组1 - Strattec Security reported quarterly earnings of $2.22 per share, exceeding the Zacks Consensus Estimate of $1.48 per share, and showing a significant increase from $0.92 per share a year ago, resulting in an earnings surprise of +50.00% [1] - The company achieved revenues of $152.4 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 5.14% and increasing from $139.05 million year-over-year [2] - Strattec Security has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has gained approximately 59.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 17.2% [3] - The company's earnings outlook is crucial for future stock performance, with current consensus EPS estimates of $0.99 for the upcoming quarter and $4.25 for the current fiscal year [7] - The Zacks Industry Rank places the Automotive - Original Equipment sector in the top 30% of over 250 Zacks industries, indicating a favorable environment for Strattec Security [8]

Core Insights - Weyerhaeuser reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of a loss of $0.07 per share, and showing an increase from earnings of $0.05 per share a year ago, resulting in an earnings surprise of +185.71% [1] - The company achieved revenues of $1.72 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 4.12% and showing growth from $1.68 billion in the same quarter last year [2] - Weyerhaeuser shares have declined approximately 17.6% year-to-date, contrasting with the S&P 500's gain of 17.2% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.09 on revenues of $1.57 billion, while for the current fiscal year, the estimate is $0.08 on revenues of $6.87 billion [7] Industry Context - The Building Products - Wood industry, to which Weyerhaeuser belongs, is currently ranked in the bottom 8% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Weyerhaeuser's stock performance [5]

Core Insights - Insmed reported a quarterly loss of $1.75 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.32, and compared to a loss of $1.27 per share a year ago [1][2] - The company achieved revenues of $142.34 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 24.16%, and up from $93.43 million year-over-year [3] - Insmed's stock has increased by approximately 141.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 17.2% [4] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.16 on revenues of $154.71 million, and for the current fiscal year, it is -$5.55 on revenues of $469.57 million [8] - The estimate revisions trend for Insmed was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [7] Industry Context - Insmed operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [9] - Another company in the same industry, Cue Biopharma, is expected to report a quarterly loss of $0.10 per share, reflecting a year-over-year change of +41.2%, with revenues projected to be $2.5 million, down 25.2% from the previous year [10]

Core Insights - Eagle Materials reported quarterly earnings of $4.23 per share, missing the Zacks Consensus Estimate of $4.35 per share, and showing a slight increase from $4.31 per share a year ago, resulting in an earnings surprise of -2.76% [1] - The company posted revenues of $638.91 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.96% and increasing from $623.62 million year-over-year [2] - Eagle Materials has underperformed the market with a 5.5% decline in share price since the beginning of the year, compared to a 17.2% gain in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $3.66 on revenues of $571.12 million, and for the current fiscal year, it is $13.99 on revenues of $2.32 billion [7] - The estimate revisions trend for Eagle Materials was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Building Products - Concrete and Aggregates industry, to which Eagle Materials belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Martin Marietta, is expected to report quarterly earnings of $6.65 per share, reflecting a year-over-year increase of 12.5%, with revenues projected at $2.05 billion, up 8.5% from the previous year [9][10]